VladimÃ-r WsÃ³l

List of Publications by Year
in descending order

94 papers	1,932 citations	279798 23 h-index	302126 39 g-index
98 all docs	98 docs citations	98 times ranked	2255 citing authors

#	Article	IF	Citations
1	Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism. Archives of Toxicology, 2021, 95, 67-78.	4.2	5
2	Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib. Biochemical Pharmacology, 2021, 192, 114710.	4.4	2
3	Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3. Cancers, 2020, 12, 3127.	3.7	7
4	Brutonâ€™s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3. Cancers, 2020, 12, 3731.	3.7	11
5	Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors. Cancers, 2020, 12, 1596.	3.7	13
6	Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?. Archives of Toxicology, 2020, 94, 3059-3068.	4.2	4
7	Initial characterization of human DHRS1 (SDR19C1), a member of the short-chain dehydrogenase/reductase superfamily. Journal of Steroid Biochemistry and Molecular Biology, 2019, 185, 80-89.	2.5	7
8	Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3. Chemico-Biological Interactions, 2019, 302, 101-107.	4.0	11
9	Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters. Biochemical Pharmacology, 2019, 163, 290-298.	4.4	9
10	Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment. Biochemical Pharmacology, 2018, 156, 22-31.	4.4	22
11	Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile. Archives of Toxicology, 2018, 92, 2845-2857.	4.2	23
12	Reductive metabolism of tiaprofenic acid by the human liver and recombinant carbonyl reducing enzymes. Chemico-Biological Interactions, 2017, 276, 121-126.	4.0	2
13	Design, Synthesis, and Biological Evaluation of Isothiosemicarbazones with Antimycobacterial Activity. Archiv Der Pharmazie, 2017, 350, 1700020.	4.1	5
14	AKR1C3 Inhibitory Potency of Naturally-occurring Amaryllidaceae Alkaloids of Different Structural Types. Natural Product Communications, 2017, 12, 1934578X1701200.	0.5	5
15	Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment. Current Neuropharmacology, 2017, 15, 637-653.	2.9	21
16	Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases. Biochemical Pharmacology, 2016, 109, 83-90.	4.4	18
17	InÂvitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chemico-Biological Interactions, 2016, 258, 153-158.	4.0	7
18	Inhibition of human anthracycline reductases by emodin â€" A possible remedy for anthracycline resistance. Toxicology and Applied Pharmacology, 2016, 293, 21-29.	2.8	18

#	Article	IF	Citations
19	Human DHRS7, promising enzyme in metabolism of steroids and retinoids?. Journal of Steroid Biochemistry and Molecular Biology, 2016, 155, 112-119.	2.5	17
20	Human dehydrogenase/reductase (SDR family) member 8 (DHRS8): a description and evaluation of its biochemical properties. Molecular and Cellular Biochemistry, 2016, 411, 35-42.	3.1	6
21	Carbonyl-reducing enzymes as targets of a drug-immobilised affinity carrier. Chemico-Biological Interactions, 2015, 234, 169-177.	4.0	2
22	Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases. Biochemical Pharmacology, 2015, 96, 168-178.	4.4	22
23	Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment. Journal of Natural Products, 2015, 78, 2666-2674.	3.0	31
24	Molecular and biochemical characterisation of human short-chain dehydrogenase/reductase member 3 (DHRS3). Chemico-Biological Interactions, 2015, 234, 178-187.	4.0	13
25	Inhibition of Nitric Oxide Synthase Prevents Muscarinic and Purinergic Functional Changes and Development of Cyclophosphamide-Induced Cystitis in the Rat. BioMed Research International, 2014, 2014, 1-12.	1.9	12
26	InÂvitro functional interactions of acetylcholine esterase inhibitors and muscarinic receptor antagonists in the urinary bladder of the rat. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 139-146.	1.9	5
27	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chemico-Biological Interactions, 2014, 220, 241-247.	4.0	17
28	Carbonyl reduction pathways in drug metabolism. Drug Metabolism Reviews, 2014, 46, 96-123.	3.6	64
29	Anthracycline resistance mediated by reductive metabolism in cancer cells: The role of aldo-keto reductase 1C3. Toxicology and Applied Pharmacology, 2014, 278, 238-248.	2.8	59
30	Purification and reconstitution of human membrane-bound DHRS7 (SDR34C1) from Sf9 cells. Protein Expression and Purification, 2014, 95, 44-49.	1.3	8
31	Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 250-258.	2.5	27
32	Biochemical properties of human dehydrogenase/reductase (SDR family) member 7. Chemico-Biological Interactions, 2014, 207, 52-57.	4.0	23
33	Synthesis and Biological Activity of Quaternary Ammonium Saltâ€Type Agents Containing Cholesterol and Terpenes. Archiv Der Pharmazie, 2014, 347, 381-386.	4.1	7
34	Deeper Insight into the Reducing Biotransformation of Bupropion in the Human Liver. Drug Metabolism and Pharmacokinetics, 2014, 29, 177-184.	2.2	38
35	Variations in the chemical profile and biological activities of licorice (Glycyrrhiza glabra L.), as influenced by harvest times. Acta Physiologiae Plantarum, 2013, 35, 1337-1349.	2.1	33
36	S-Nitrosoglutathione covalently modifies cysteine residues of human carbonyl reductase 1 and affects its activity. Chemico-Biological Interactions, 2013, 202, 136-145.	4.0	9

#	Article	IF	Citations
37	Efficient isolation of carbonylâ€reducing enzymes using affinity approach with anticancer drug oracin as a specific ligand. Journal of Separation Science, 2013, 36, 1176-1184.	2.5	2
38	Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetonein vitro. Xenobiotica, 2013, 43, 346-354.	1.1	33
39	A Simple Identification of Novel Carbonyl Reducing Enzymes in the Metabolism of the Tobacco Specific Carcinogen NNK. Drug Metabolism Letters, 2013, 6, 174-181.	0.8	5
40	Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase. Tuberculosis, 2012, 92, 434-439.	1.9	73
41	Expression of human carbonyl reductase 3 (CBR3; SDR21C2) is inducible by pro-inflammatory stimuli. Biochemical and Biophysical Research Communications, 2012, 420, 368-373.	2.1	9
42	Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: well-known and promising members of the SDR superfamily. Drug Metabolism Reviews, 2012, 44, 173-191.	3.6	33
43	Synthesis and inÂvitro antimycobacterial and isocitrate lyase inhibition properties of novel 2-methoxy-2â€²-hydroxybenzanilides, their thioxo analogues and benzoxazoles. European Journal of Medicinal Chemistry, 2012, 56, 108-119.	5.5	20
44	Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase. Chemico-Biological Interactions, 2011, 191, 66-74.	4.0	29
45	Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29. Chemico-Biological Interactions, 2011, 191, 239-249.	4.0	48
46	Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3. Chemico-Biological Interactions, 2011, 191, 95-103.	4.0	21
47	Enzyme Stereospecificity as a Powerful Tool in Searching for New Enzymes. Current Drug Metabolism, 2010, 11, 547-559.	1.2	6
48	Human Carbonyl Reductases. Current Drug Metabolism, 2010, 11, 639-658.	1.2	64
49	Stereospecific reduction of the original anticancer drug oracin in rat extrahepatic tissues. Journal of Pharmacy and Pharmacology, 2010, 55, 1003-1011.	2.4	1
50	Characterization of enzymes responsible for biotransformation of the new antileukotrienic drug quinlukast in rat liver microsomes and in primary cultures of rat hepatocytes. Journal of Pharmacy and Pharmacology, 2010, 56, 205-212.	2.4	5
51	The stereoselective biotransformation of the anti-obesity drug sibutramine in rat liver microsomes and in primary cultures of rat hepatocytes. Journal of Pharmacy and Pharmacology, 2010, 57, 405-410.	2.4	12
52	Reduction of the Potential Anticancer Drug Oracin in the Rat Liver In-vitro. Journal of Pharmacy and Pharmacology, 2010, 52, 495-500.	2.4	15
53	AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chemico-Biological Interactions, 2009, 178, 138-144.	4.0	56
54	Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin. Toxicology, 2009, 264, 52-60.	4.2	12

#	Article	IF	Citations
55	Structural Basis for Substrate Specificity in Human Monomeric Carbonyl Reductases. PLoS ONE, 2009, 4, e7113.	2.5	47
56	Inactivation of the anticancer drugs doxorubicin and oracin by aldoâ€“keto reductase (AKR) 1C3. Toxicology Letters, 2008, 181, 1-6.	0.8	69
57	Liquid chromatographicâ€“electrospray mass spectrometric determination (LCâ€“ESI-MS) of phase II metabolites of flobufen in rat liver microsomesâ€”Chiral discrimination. Talanta, 2008, 75, 494-502.	5.5	3
58	Coordination Compounds Based on 1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic Acid. Molecules, 2007, 12, 1064-1079.	3.8	4
59	Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man. Toxicology, 2007, 238, 111-118.	4.2	33
60	11Î²-Hydroxysteroid dehydrogenase type 1: Purification from human liver and characterization as carbonyl reductase of xenobiotics. Molecular and Cellular Endocrinology, 2006, 248, 34-37.	3.2	17
61	Hydantoins and Thiohydantoins Derived from 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid. Heterocycles, 2006, 68, 2527.	0.7	4
62	Liquid chromatographyâ€“tandem mass spectrometry in chiral study of amlodipine biotransformation in rat hepatocytes. Analytica Chimica Acta, 2006, 573-574, 273-283.	5.4	14
63	Metabolite profile of sibutramine in human urine: a liquid chromatography-electrospray ionization mass spectrometric study. Journal of Mass Spectrometry, 2006, 41, 1171-1178.	1.6	24
64	PURIFICATION AND CHARACTERIZATION OF AKR1B10 FROM HUMAN LIVER: ROLE IN CARBONYL REDUCTION OF XENOBIOTICS. Drug Metabolism and Disposition, 2006, 34, 464-470.	3.3	106
65	Use of chiral liquid chromatography for the evaluation of stereospecificity in the carbonyl reduction of potential benzo[c]fluorene antineoplastics benfluron and dimefluron in various species. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 1049-1057.	2.8	6
66	Liver microsomal biotransformation of albendazole in deer, cattle, sheep and pig and some related wild breeds. Journal of Veterinary Pharmacology and Therapeutics, 2005, 28, 377-384.	1.3	18
67	Albendazole repeated administration induces cytochromes P4501A and accelerates albendazole deactivation in mouflon (Ovis musimon). Research in Veterinary Science, 2005, 78, 255-263.	1.9	13
68	Chiral Inversion of Drugs: Coincidence or Principle?. Current Drug Metabolism, 2004, 5, 517-533.	1.2	90
69	Stereospecificity of flobufen metabolism in guinea pigs in vitro and in vivo: Phase I of biotransformation. Chirality, 2004, 16, 1-9.	2.6	21
70	The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11Î²-hydroxysteroid dehydrogenase type 1. Toxicology, 2004, 197, 253-261.	4.2	20
71	HPLCâ€”radiometric determination of quinlukast in biological fluids. Journal of Pharmaceutical and Biomedical Analysis, 2004, 35, 177-183.	2.8	2
72	Comparison of in vitro activities of biotransformation enzymes in pig, cattle, goat and sheep. Research in Veterinary Science, 2004, 76, 43-51.	1.9	89

#	Article	IF	Citations
73	The Phase I Biotransformation of the Potential Antileukotrienic Drug Quinlukast in Rat Microsomes and Hepatocytes. Collection of Czechoslovak Chemical Communications, 2004, 69, 689-702.	1.0	4
74	Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11Î²-hydroxysteroid dehydrogenase type 1. Chemico-Biological Interactions, 2003, 143-144, 459-468.	4.0	23
75	Reduction of flobufen in pig hepatocytes: Effect of pig breed (domestic, wild) and castration. Chirality, 2003, 15, 213-219.	2.6	3
76	Chiral aspects of metabolism of antiinflammatory drug flobufen in human hepatocytes. Chirality, 2003, 15, 433-440.	2.6	7
77	Stereoselective pharmacokinetics and metabolism of flobufen in guinea pigs. Chirality, 2003, 15, 724-729.	2.6	6
78	The stereospecificity of flobufen metabolism in isolated guinea pig hepatocytes. BMC Pharmacology, 2003, 3, 5.	0.4	4
79	Stereospecific biotransformation of albendazole in mouflon and rat-isolated hepatocytes. Journal of Veterinary Pharmacology and Therapeutics, 2003, 26, 297-302.	1.3	12
80	Central composite design as a powerful optimisation technique for enantioresolution of the rac-11-dihydrooracinâ€”the principal metabolite of the potential cytostatic drug oracin. Journal of Proteomics, 2002, 54, 377-390.	2.4	23
81	Carbonyl reduction of the potential cytostatic drugs benfluron and 3,9-dimethoxybenfluron in human in vitro. Biochemical Pharmacology, 2002, 64, 297-305.	4.4	21
82	3-Phenyl-5-acyloxymethyl-2H,5H-furan-2-ones:â€‰ Synthesis and Biological Activity of a Novel Group of Potential Antifungal Drugs. Journal of Medicinal Chemistry, 2001, 44, 2701-2706.	6.4	71
83	Stereospecificity and stereoselectivity of flobufen metabolic profile in male rats in vitro and in vivo: Phase I of biotransformation. Chirality, 2001, 13, 754-759.	2.6	12
84	Biotransformation of flobufen enantiomers in ruminant hepatocytes and subcellular fractions. Chirality, 2001, 13, 760-764.	2.6	5
85	Effect of ivermectin on activities of cytochrome P450 isoenzymes in mouflon (Ovis musimon) and fallow deer (Dama dama). Chemico-Biological Interactions, 2001, 137, 155-167.	4.0	29
86	Activity, stereospecificity, and stereoselectivity of microsomal enzymes in dependence on storage and freezing of rat liver samples. Chirality, 2000, 12, 649-653.	2.6	1
87	Effect of substituents on microsomal reduction of benzo(c)fluorene N-oxides. Chemico-Biological Interactions, 2000, 126, 185-200.	4.0	10
88	Metabolic pathways of flobufen â€” a new antirheumatic and antiarthritic drug. Interspecies comparison. Experimental and Toxicologic Pathology, 1999, 51, 352-356.	2.1	10
89	Stereoselective pharmacokinetics of flobufen in rats. , 1999, 11, 781-786.		8
90	Sex differences in stereospecificity of oracin reductases in ratin vitro andin vivo. , 1999, 11, 505-509.		13

#	Article	IF	Citations
91	A comparison between stereospecificity of oracin reduction and stereoselectivity of oxidation of 11-dihydrooracin enantiomersin vitro in rat and guinea pig. , 1999, 11, 510-515.		8
92	High-performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin. Journal of Chromatography A, 1998, 797, 197-201.	3.7	15
93	Separation of the stereoisomers of the main metabolite of a non-steroidal anti-inflammatory drug, flobufen, by chiral high-performance liquid chromatography. Biomedical Applications, 1997, 689, 205-214.	1.7	8
94	High-performance liquid chromatographic assay for the separation and characterization of metabolites of the potential cytostatic drug oracine. Biomedical Applications, 1996, 681, 169-175.	1.7	29